Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Mind Medicine Mindmed Inc (MNMD)

Mind Medicine Mindmed Inc (MNMD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,367,305
  • Shares Outstanding, K 98,509
  • Annual Sales, $ 0 K
  • Annual Income, $ -108,680 K
  • EBIT $ -151 M
  • EBITDA $ -150 M
  • 60-Month Beta 2.57
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 8.14

Options Overview Details

View History
  • Implied Volatility 77.46% (-5.81%)
  • Historical Volatility 52.75%
  • IV Percentile 20%
  • IV Rank 18.29%
  • IV High 151.81% on 02/05/25
  • IV Low 60.82% on 08/07/25
  • Expected Move (DTE 3) 0.94 (6.34%)
  • Put/Call Vol Ratio 0.12
  • Today's Volume 4,884
  • Volume Avg (30-Day) 2,452
  • Put/Call OI Ratio 0.21
  • Today's Open Interest 72,069
  • Open Int (30-Day) 60,180
  • Expected Range 13.93 to 15.81

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.48
  • Number of Estimates 4
  • High Estimate -0.37
  • Low Estimate -0.54
  • Prior Year -0.41
  • Growth Rate Est. (year over year) -17.07%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.00 +23.92%
on 12/16/25
15.29 -2.75%
on 01/08/26
+2.32 (+18.49%)
since 12/12/25
3-Month
10.46 +42.10%
on 11/21/25
15.29 -2.75%
on 01/08/26
+2.62 (+21.39%)
since 10/13/25
52-Week
4.70 +216.38%
on 04/09/25
15.29 -2.75%
on 01/08/26
+8.38 (+128.95%)
since 01/13/25

Most Recent Stories

More News
Wall Street Thinks This 1 Psychedelic Stock Can Gain 335% in 2026

As mental health treatment evolves, MindMed’s advancing psychedelic pipeline and strong 2025 rally have Jones Trading penciling in gains that could more than quadruple the stock from here.

MNMD : 14.87 (+7.13%)
MarketBeat’s Top 5 Rated Small-Cap Stocks

Small-cap stocks are regaining momentum as rate cuts and the end of quantitative tightening drive a renewed risk-on environment.

ATAI : 3.67 (-2.39%)
TRVI : 11.29 (unch)
CRMD : 7.06 (-1.26%)
TREE : 62.41 (+6.10%)
MNMD : 14.87 (+7.13%)
IWM : 261.35 (-0.06%)
MindMed to Present at the 44th Annual J.P. Morgan Healthcare Conference

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today...

MNMD : 14.87 (+7.13%)
MindMed Announces New Employee Inducement Grant

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today...

MNMD : 14.87 (+7.13%)
MindMed Announces New Employee Inducement Grants

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today...

MNMD : 14.87 (+7.13%)
MindMed Reports Q3 2025 Financial Results and Business Updates

-- Anticipated topline data readouts on track for ongoing Phase 3 studies of MM120 Orally Disintegrating Tablet (ODT) in GAD: Voyage (1H 2026) and Panorama (2H 2026)-- ...

MNMD : 14.87 (+7.13%)
MindMed to Participate in Upcoming Investor Conferences

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today...

MNMD : 14.87 (+7.13%)
MindMed Announces New Employee Inducement Grant

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today...

MNMD : 14.87 (+7.13%)
Mind Medicine (MindMed) Inc. Announces Closing of Approximately $259 Million Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

Mind Medicine (MindMed) Inc . (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders,...

MNMD : 14.87 (+7.13%)
MindMed to Report Q3 2025 Financial Results on November 6, 2025

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today...

MNMD : 14.87 (+7.13%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Mind Medicine Inc. is a clinical-stage psychedelic medicine biotech company. It discovers, develops and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. Mind Medicine Inc. is based in New York, United States.

See More

Key Turning Points

3rd Resistance Point 16.81
2nd Resistance Point 16.00
1st Resistance Point 15.44
Last Price 14.87
1st Support Level 14.07
2nd Support Level 13.26
3rd Support Level 12.70

See More

52-Week High 15.29
Last Price 14.87
Fibonacci 61.8% 11.24
Fibonacci 50% 9.99
Fibonacci 38.2% 8.75
52-Week Low 4.70

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar